Content uploaded by Duarte Nuno da Silva Marques
Author content
All content in this area was uploaded by Duarte Nuno da Silva Marques on Feb 09, 2022
Content may be subject to copyright.
J.Clin.Med.2022,11,894.https://doi.org/10.3390/jcm11030894www.mdpi.com/journal/jcm
Article
GuidedBoneRegenerationintheEdentulousAtrophicMaxilla
UsingDeproteinizedBovineBoneMineral(DBBM)Combined
withPlatelet‐RichFibrin(PRF)—AProspectiveStudy
JoãoManuelMendezCaramês
1,2,3,
*,FilipeAraújoVieira
1
,GonçaloBártoloCaramês
1
,AnaCatarinaPinto
1
,
HelenaCristinaOliveiraFrancisco
1,2
andDuarteNunodaSilvaMarques
1,2,3
1
InstitutodeImplantologia,AvenidaColumbanoBordaloPinheiro,nº50,1070‐064Lisbon,Portugal;
fmaraujo.vieira@gmail.com(F.A.V.);caramesgoncalo@gmail.com(G.B.C.);
anacatarina.pinto@institutoimplantologia.com(A.C.P.);helenafrancisco@campus.ul.pt(H.C.O.F.);
duarte.marques@campus.ul.pt(D.N.d.S.M.)
2
FaculdadedeMedicinaDentária,UniversidadedeLisboa,1600‐277Lisbon,Portugal
3
LIBPhys‐FCTUID/FIS/04559/2013,FacultyofDentalMedicine,UniversityofLisbon,
1600‐277Lisbon,Portugal
*Correspondence:carames@campus.ul.pt;Tel.:+351‐91972‐7353;Fax:+351‐21721‐0989
Abstract:Background:Boneregenerationproceduresrepresentamajorchallengeinoralsurgery.
ThisstudyaimedtoevaluateacompositePRF/particulatexenograftinguidedboneregeneration.
Methods:Edentulouspatientswithhorizontalridgedeficienciesintheanteriormaxillaand
candidatestoanimmediate‐loadingfull‐archrehabilitationwereincluded.Horizontallinear
measurementsindicatingbonegainwereassessedfromcomputerbeamcomputertomography
(CBCT)scansobtainedatpre‐surgery,post‐surgery,andthe12‐monthfollow‐up.Meanbonevalues
werepresentedasmean±95%CI.Non‐parametrictestswereusedasappropriate,andtheeffect
sizewascalculatedwithCohen’sdrepeatedmeasures.Results:Eighteenpatientswererehabilitated
with72implants.Themeanhorizontalbonewidthwas4.47[4.13–4.80]mmpre‐surgically,9.25
[8.76–9.75]mmpost‐surgically,and7.71[7.28–8.14]mm12monthsafter.Conclusions:PRF
associatedwithaxenograftseemstopromoteaneffectivehorizontalbonegain.Randomized
clinicaltrialsareneededtoconfirmthebenefitsofthissurgicalapproach.
Keywords:platelet‐richfibrin;deproteinizedbovinebonemineral;guidedboneregeneration;
horizontalaugmentation;atrophicmaxilla;naturalscaffold
1.Introduction
Theatrophicmaxillarepresentsasurgicalandprosthodonticchallengeforan
implant‐supportedreconstruction[1,2].Withinthefirst6monthsfollowingananterior
toothextraction,themaxillaexhibitsaprimaryvolumetricchangerangingfrom29to63%
horizontallyand11to22%vertically[3].Thepresenceofperiodontaldisease,trauma,
otherhard‐tissueinfections,orcongenitalmalformationsworsensthisboneloss,which
continuouslyprogressesovertheyearsfollowingacentripetalpattern[4,5].Cawoodand
Howell’sclassificationdescribesdifferentstagesofmaxillaatrophyassociatedwiththe
collapseofthecircumoralmusculature,triggeringmouthnarrowing,lossoflipsupport,
andinversionofthelips[6].Thislatteraspectismoresignificantintheanteriormaxilla
[7–9].
Despitethecurrentperspectivetowardaminimallyinvasivegraftlessapproach,itis
recognizedthatmostedentulousmaxillaedemandsometypeofboneaugmentation
procedure[10,11].Implantsinthegraftlessedentulousmaxillashowhighsurvivalrates
butarenotexemptfromsideeffectsorprosthodonticcomplications[12].Moreover,the
Citation:Caramês,J.M.M.;
Vieira,F.A.;Caramês,G.B.;
Pinto,A.C.;Francisco,H.C.O.;
Marques,D.N.d.S.GuidedBone
RegenerationintheEdentulous
AtrophicMaxillaUsing
DeproteinizedBovineBoneMineral
(DBBM)CombinedwithPlatelet‐
RichFibrin(PRF)—AProspective
Study.J.Clin.Med.2022,11,894.
https://doi.org/10.3390/jcm11030894
AcademicEditors:
MarkA.Reynolds
Received:13January2022
Accepted:7February2022
Published:8February2022
Publisher’sNote:MDPIstays
neutralwithregardtojurisdictional
claimsinpublishedmapsand
institutionalaffiliations.
Copyright:©2022bytheauthors.
LicenseeMDPI,Basel,Switzerland.
Thisarticleisanopenaccessarticle
distributedunderthetermsand
conditionsoftheCreativeCommons
Attribution(CCBY)license
(https://creativecommons.org/license
s/by/4.0/).
J.Clin.Med.2022,11,8942of14
levelofboneatrophyhasbeenreportedtoimpactrestorativeandregenerativetreatment
schemesinafixedfull‐archrehabilitation[13].Itisclearthatboneregenerationprioror
simultaneouslytoimplantplacementinafixedfull‐archrehabilitationinthemaxillais
essentialnotonlyforaprosthodonticallydrivenconceptbutalsotopromotelocalbone
defectandfacialaestheticcorrections[6].Manytechniques,suchasridgesplitting,bone
blockgrafting,orguidedboneregeneration(GBR)combinedwithseveralbonegrafts
(autografts,allografts,xenografts,andalloplasts)ordifferenttypesofmembranesor
mesheshavebeendescribedtohorizontallyreconstructanalveolarridgeintheanterior
region[14–17].Despitetheplethoraofprocedures,themostadequateoptiontoobtaina
stablehorizontalbonedimensionincreaseandalong‐termimplantandprosthesis
survivalrateisyetundetermined[15,18,19].
Basedonhigh‐evidencelevelpublications,GBRseemsmorepredictable,
reproducible,andtoresultinfewercomplicationsthanothertechniques[12,15,20].GBR
entailsusingamechanicalhindrance—usuallyaresorbableoranon‐resorbable
membrane—toseparatethebonydefectfromepithelialandconnective‐tissueingrowth,
allowingcreatingaspaceforosteogeniccellstoproliferate[21].Theneedforoptimizing
horizontalbonegainandacceleratingbonetissueformationhashighlightedthe
importanceofaddinggrowthfactorstoGBRprocedures[22].
Abettercomprehensionofthecellulareventsthatregulatebonetissueformation
unveiledtherationalebehindnaturalbiologicalmediators.Accordingly,inorderto
enhanceangiogenesis,stemcellmigration,andosteogenicdifferentiationinherenttothe
regenerativeprocedure,severalauthorshavesuggestedthepotentialofgrowthfactorsto
bonegraftsandtissuehealing,mainlyusingautologousplateletconcentrates(APCs)
[22,23].Sincethat,theefficacyofplateletconcentratesinpromotingwoundhealingand
tissueregenerationhasbeenthecenterofanenrichedandparticipatedacademicdebate.
In2005,Dohanetal.namedasecondgenerationofAPCsasPRF,richinplatelets,
leukocytes,andmonocytes[24].PRFisobtainedaccordingtoastandardizedprotocolby
venipunctureand2700‐rpmcentrifugationfor12min,withoutusinganticoagulants
[25,26].Itconsistsofanetworkofnanoscalefibersofferinganaturalscaffoldforcell
proliferation,migration,anddifferentiation[27].Additionally,itslowlyreleasescrucial
growthfactorsduring10to14days,suchasPDGF,TGF‐β1,IGF,andVEGF[27].These
factorsplayanimportantroleintissuehealing[23].Accordingtoarecentrandomized
clinicaltrial,PRFhasproventopromotewoundhealingafterdentalextraction[28].
AliquidpresentationofPRF,fibrinogen,canalsobeobtainedbymodifying
centrifugationforces[27].ThisflowablePRFmayberegardedasanautologousbinder,
aggregatinggraftbiomaterial,andchoppedPRFmembranesinacomposite
PRF/particulatexenograftasusedinthisprospectivestudy.Clinicalresearchhasshown
promisingresultsfromtheassociationofPRFandparticulatebonegraftsinregenerative
procedures[29].However,accordingtoarecentsystematicreview,limitedstudies
investigateitsapplicationinintraoralbonegrafting,especiallyinhorizontalandvertical
boneaugmentation[30].
Basedonthedescribedbackground,thisstudyaimstoprospectivelytest
deproteinizedbovinebonemineral(DBBM)combinedwithPRFinGBRsimultaneously
toimplantplacementinedentulouspatientswithanteriormaxillaryatrophywhoare
candidatesforimmediate‐loadingfull‐archrehabilitation.
2.MaterialsandMethods
2.1.PatientSelection
Thisstudywasasingle‐armprospectiveclinicalstudywithapre‐postdesign,carried
outbetweenDecember2015andJanuary2018.Thestudyprotocolwasapprovedbythe
LocalEthicalCommitteewiththeID:II2015‐06andregisteredatClinicalTrials.gov(U.S.
NationalLibraryofMedicine,Bethesda,MD,USA)withtheregistrationNCT03391258.
J.Clin.Med.2022,11,8943of14
AlltreatmentphaseswereconductedpertheHelsinkiDeclarationof1975,asrevisedin
2008.
Eighteenpatientswereincludedinthisstudyandsignedthewrittenconsentforms
beforesurgery.Patientswereconsecutivelyrecruitedaccordingtothefollowinginclusion
criteria:(1)beingover18yearsofage;(2)beingASAIorASAIIwithmildsystemic
disease;(3)beingedentulousorpartiallyedentulouswithfailingteethindicatedfora
fixedfull‐archreconstruction;(4)havingahorizontalbonedefectintheanteriormaxilla;
(5)havingananteriorridgewidthallowingforlateralboneaugmentationsimultaneously
toimplantplacement;(6)beingcomplianttoparticipateinaclinicalstudy.Theexclusion
criteriaconsideredwere:(1)ASAIIIorASAIV;(2)oncologichistoryand/orchemo‐and
radiotherapytreatmentsintheprevioustwoyears;(3)havingahorizontalbonedefect
causedbytumorresection;(4)pregnantwomen;(5)uncontrolleddiabetes;(6)taking
immunosuppressantmedicationormedicationrelatedtoosteonecrosisofthejaw
(MRONJ);(7)heavysmokinghabits(overtencigarettes);(8)hematologicdiseases;(9)any
typeofpsychiatricdisorders;(10)participatinginanotherclinicalstudy.
Theprimaryoutcomemeasurewasdefinedasthelinearhorizontalbonegain(mm)
immediatelyaftersurgeryand12monthslater,measuredbyCBCTpost‐surgicallyandat
the12‐monthfollow‐up.Thesecondaryoutcomemeasuresweretherateofaugmented
bonestabilityatthe12‐monthfollow‐up,theincidenceofpost‐operatorycomplications
(softtissuedehiscence,sensorydisorder,woundinfection,orgraftexposure)recordedat
10daysand1monthaftersurgery,andimplantsurvival.
2.2.OutcomesAssessment
Foreachpatient,CBCT(CBCTPlanmecaProMaxDimax3DigitalPlan/Ceph)scans
wereobtainedpre‐surgery,immediatelyafterthesurgery(post‐surgery),andatthe12‐
monthfollow‐up.Theywereperformedwitha0.20voxelsize,80kV,and15mA,within
anexposuretimeof12saccordingtothemanufacturer’sinstructions.Cross‐sectional
imageswerereconstructedtoa0.6‐mmthickslicewiththeartifactremovaloption
applied.Twoindependent,calibratedoperators(D.M.;A.P.)assessedeachCBCTscan,
andwhenindisagreement,meanvaluesbetweentheirmeasurementswerecalculated.
Forthepurposeofthisstudy,onlythepre‐maxillaregion,delimitedbytheanterior
bordersofthemaxillarysinus,wasanalyzed,regardlessofimplantplacementinthe
posteriormaxillaryareas.Fourimplantswereanalyzedperpatientinthelocationsofthe
formerlateralincisorsandfirstpremolars.Inthesagittalcuts,eachimplant’slengthwas
measuredfromthenecktothetop.Site1forlinearbonemeasurementwastheneckofthe
implant,perpendiculartothelongaxisoftheimplant.Site2forlinearbonemeasurements
wasthemiddlepointofthetotallengthoftheimplant.Bothsitesweremeasuredfromthe
mostpalatalpointtothemostbuccalpoint(Figure1A–C).Thefollowingvariableswere
determinedinsites1and2,andmeanvalueswerecalculatedtoassesstheoutcomesof
thisstudy.
J.Clin.Med.2022,11,8944of14
Figure1.Exampleofmeasurementsinthreeimplantsitesfromdifferentpatients(A–C)evaluated
throughCBCTscansusingthePlanmecaRomexisVersion2.5.1.R.Imagescorrespondto
measurementsinthedifferentperiods:beforetreatment,aftertreatment,andatthe12‐month
follow‐up.
Implantpositioninthepre‐surgicalCBCTscanwasobtainedfromthepost‐surgical
CBCTscanaccordingtoapreviouslydescribedmethodology[31].Ontheaxialviewof
thepost‐surgicalCBCT,inthemidlineofthemaxilla,theneareranatomicreproducible
landmark(nasalspine,incisiveforamen,maxillarysinusanteriorwall)wasidentified,and
astraightlinewasdrawntotheneckoftheimplant.Thedistancewasobtainedusingthe
PlanmecaRomexissoftware’srulerandreplicatedinthepre‐surgicalCBCTscan.The
pre‐surgicalwidth(mm)wasmeasuredfromthecorticalbone’spalatalpointtothenative
bone’sbuccalpoint,perpendiculartothelongaxisoftheimplantposition.Thepost‐
surgicalwidth(mm)wasmeasuredfromthecorticalbone’spalatalpointtothe
regeneratedbone’sbuccalpoint,perpendiculartothelongaxisoftheimplant.The
augmentedhorizontalbonewidth(mm)wascalculatedbythedifferencebetweenpre‐
andpost‐surgicalCBCTlinearmeasurements.Thesamemethodwasusedtocalculatethe
horizontalregeneratedbonegainoneyearaftersurgery,usingasreferencethepost‐
surgicalandthe12‐monthlinearmeasurements.
2.3.ClinicalProcedures
Invisit1,inclusionandexclusioncriteriawerescreenedforeachparticipant.After
anamnesisandclinicalexamination,participantsunderwentpreoperativeprosthetic
preparation(analysisofaestheticfeatures,suchasfacialprofile,lipsupport,smileline,
andresidualridgeexposure).Subsequently,afterthepatientsignedtheinformedconsent,
apre‐surgicalCBCTscan(PlanmecaRomexis,Planmeca,Helsinki,Finland)was
performedtoevaluatemaxillaryresorption,whichallowedplanningforimplantposition
andboneaugmentationprocedures.
Invisit2,onthedayofsurgery,PRFmembranes,acompositeformedbyparticulate
xenograft(Bio‐Osssmallparticles,GeistlichAG,Wolhusen,Switzerland),andan
averageofeightPRFmembranesandliquidfibrinogenwereobtainedaccordingtoa
(A)
J.Clin.Med.2022,11,8945of14
describedprotocol(Figure2A–C)[26].Allsurgicalprocedureswereperformedunder
strictsterileconditions,andeachpatientsubmittedtolocalanesthesia(articaine4%with
epinephrine1:200,000,Inibsa,Sintra,Portugal),bothbuccallyandpalatally.Amidcrestal
incisionwasperformed,followedbyamucoperiostealflaprelease(totalthickness)to
exposethefullextensionofthebuccalbonedefect(Figure3A,B).Inpartiallyedentulous
patients,theremainingteethwereextractedintheleasttraumaticwaytoavoidtissue
damage,andanosteotomywasperformedtoleveltheboneheightandimprovethe
prosthodonticdesignandfeatures.Regardlessofimplantneedsintheposteriorregionof
themaxilla,fourimplantswereplacedintheformerpositionsofthelateralincisorsand
firstpremolars(Straumann
®
BoneLevelTaperedImplants,Basel,Switzerland)witha
minimumconfirmedprimarystabilityvalueof45Ncmineachimplant(Figure3C).The
compositePRF/particulateDBBMpreparedwasappliedinthebuccalplateofthepre‐
maxillaandshapedtorestorebonevolume.Thegraftedareawasthencoveredwithat
leastfourlayersofPRFmembranestoprotectitfromexposureandoptimizewound
healing(Figure3D,E).Atensionlessprimaryclosurewasobtainedthroughhorizontal
periostealreleasing,flapadvancement,andsimplesuturesusinganon‐resorbablesuture
(6‐0polypropylenePermaSharp
®
Sutures,Hu‐Friedy,Chicago,IL,USA).
Figure2.ClinicalphotographsoftheprotocolsequencetoobtainthecompositePRF/particulate
xenograft:(A)ExtractionofthePRFmembranesfromthered‐toppedtubes.Themembraneswere
posteriorlypressedinapropermetalbox;(B)Irrigationofautologousboneandxenograftwith
liquidfibrinogenobtainedfromthewhite‐toppedtubes;(C)ObtainingacompositePRF/particulate
xenograft.Notethestiffnessofthiscomposite,whichacquiredarectangularform.
J.Clin.Med.2022,11,8946of14
Figure3.Clinicalphotographsofsequentialsurgicalstages:(A)Atrophicmaxillaofapartially
edentulouspatientwhoworearemovableprosthesisformorethan15years;(B)Incisionandfull‐
thicknessflapreleasing.Notethethinbuccalplate;(C)Implantplacement.Notethebuccal
fenestrationoftheimplantsinthepre‐maxilla;(D)Guidedboneregenerationwithacomposite
PRF/particulatexenografttoreconstructthebuccalaspectofthemaxilla;(E)Overlayofthe
compositePRF/particulatexenograftwithatleastfourPRFmembranes,providingprotectionofthe
graftedarea;(F)Full‐archimplant‐supportedprovisionalrestorationplacedaftersurgery.
Immediatemetal‐reinforcedfixedcompletedenturesweremade,inserted,and
adjustedonthesamedayofsurgerytoserveasimmediateprovisionalrestorationsduring
healingandosseointegration(Figure4F).Manufactureandinsertionandadjustment
proceduresfollowedtheprinciplesdescribedbyCaramesetal[32].Patientswere
medicatedwithamoxicillin+clavulanicacid875/125mg(startingthedaybeforesurgery
withonetabletevery12h,for8days),600mgofibuprofen(every12hfor3days),and1
gofparacetamol(every8h,forthefirstthreedays)Theywerealsoinstructedtorinse
twiceadaywithchlorhexidine(PerioAid0.12%;Dentaid,Spain)mouthrinseandnot
brushthesurgicalareauntilsutureremovalatday10.
Figure4.Clinicalphotographsreportingtherelevanceoftheissuepresentedinthisstudy.
Evaluationoftheaestheticfeaturesrelatedtolipsupportandprosthesis,aswellassofttissue
healingandemergenceprofileatthe12‐monthfollow‐upappointment.(A)Lipsupportatrest
J.Clin.Med.2022,11,8947of14
beforetreatment;(B)Lipsupportatrestatthe12‐monthfollow‐upappointment;(C)Lipsupportat
smilingpositionbeforetreatment;(D)Lipsupportatsmilingpositionatthe12‐monthfollow‐up
appointment;(E)Emergencyprofileofthesiximplantsplacedinthemaxilla.(F)Superiorand
inferiorfull‐archprosthesisinmonolithiczirconia.Notethatthemaxillaryprosthesisincludeda
veryreducedbuccalflangeduetothehardandsoftregenerationobtainedaftersurgery.
Patientsweresubmittedtomandatorypost‐surgicalcontrolappointmentsat10days,
1month,and6monthsaftersurgery,andothersifneeded.Atthe10‐dayand1‐month
follow‐upappointments,post‐operatorycomplications,suchassensorydisorder,
infection,graftexposure,anddehiscencewereassessed,andthenumberofeventswas
determined.Atthe1‐yearfollow‐upappointment,participantswerealsosubmittedtoa
clinicalobservationtomonitoraestheticfeaturesrelatedtolipsupportascomparedto
baseline(Figure4A–D),prostheses,softtissuehealing,andtheemergenceprofile(Figure
4E,F).
2.4.StatisticalAnalysis
AllthecollecteddatawereprocessedinSPSSsoftware(version24;IBMSPSS
Statistics,Chicago,IL,USA)forstatisticalanalysis.Resultswereexpressedasamean±
95%confidenceinterval(CI)inmillimetersforlinearbonemeasurementsorasa
percentageforaugmentedbone.NormalityofdistributionwastestedbyShapiro–Wilk’s
normalitytest,andLevene’stestwasusedtoassesstheequalityofvariance.Accordingto
thevariablestobeassessed,thenon‐parametricFriedman’s,Mann–WhitneyU,or
Kruskal–Wallistestswereusedtocompareoverallordifferentsitesforregeneratedbone
linearchanges(α =0.05)usingthepatientasthestatisticalunit.Theeffectsizewas
calculatedwithCohen’sdrepeatedmeasuresbetweenpre‐ andpost‐surgical
measurementsandbetweenpost‐surgicaland12‐monthfollow‐upmeasurements,and
consideredassmall(<0.3),moderate(0.3–0.8),orlarge(≥0.8)effect.Asamplesize
determinationwasperformedtodetectalargeeffect(≥0.8)inbonegainatthe12‐month
follow‐upappointment,usingG*Power3.1software(Heinrich‐Heine‐Universität,
Düsseldorf,Germany).Consideringasignificancelevelof5%andapowerof80%,a
minimumof12participantswasrequired.Tooffsetapossibleattritionbias,50%was
addedtothetotalsample,resultingin18patients.Anindependentstatisticianperformed
thestatisticalanalysis.
3.Results
The18participantsincludedfivemenand13women,withagesrangingfrom36to
76years(mean:58years).Sevenweresmokers(lessthantencigarettesperday).No
dropoutswereregistered.Thisstudyassessedatotalof72implants,ofwhichonewas
lostduringthefollow‐upperiod,equatingtoasurvivalrateof98.61%.
Table1presentshorizontalbonechangespersiteatdesignatedtimepoints:pre‐
surgery(beforetreatment),post‐surgery(aftertreatment),anda12‐monthfollow‐up.For
bothsites,thepost‐surgicaland12‐monthfollow‐uphorizontalwidthwasstatistically
higher(Friedman’stest,p<0.05)thanthepre‐surgicalvalues,withadrepeatedmeasuresof2.38
[2.07;2.67]and1.66[1.39;1.94],respectively.Site2alsoshowedstatisticallyhighervalues
thansite1atthepost‐surgicaland12‐monthfollow‐upCBCTs(Figure5).Themean
horizontalwidthatthe12‐monthfollow‐upwasstatisticallydifferentfromthepre‐and
post‐surgeryvalues(Friedman’stest,p<0.05),withadrepeatedmeasuresof−1.12[−1.38;−0.86]
betweenthepost‐surgicalandthe12‐monthfollow‐uphorizontalwidths.Theobtained
effectsizeswereabovetheminimumdetectableeffectsizeof0.098,withanalfaof0.05
andabetaof0.2.Theoverallmeanaugmentedbonegainatpost‐opwas4.54mm[4.09;
4.98]withstatisticallysignificantdifferencesbetween3.96[3.51;4.41]mmforsite1and
4.96[4.32;5.60]mmforsite2(Mann–WhitneyUtest,p<0.05).Nosignificantdifferences
weredetectedwhencomparingaugmentedbonestabilitybetweensites(Mann–Whitney
Utest,p>0.05)orimplantlocationsintheaestheticarea(Kruskal–Wallis,p>0.05).
J.Clin.Med.2022,11,8948of14
Table1.Linearbonechanges(inmm)foreachlocationandoverallatdifferentevaluationtimes.
Pre‐SurgeryPost‐Surgery12‐MonthFollow‐UpBoneGain(12Months—Pre‐Surgery)
Site1
Mean3.527.796.533.01
95%CI3.19–3.857.30–8.286.09–6.962.51–3.50
Range6.167.536.68.17
Site2
Mean5.510.848.993.5
95%CI5.04–5.9510.19–11.488.42–9.572.87–4.13
Range8.599.768.478.46
Total
Mean4.479.257.713.24
95%CI4.13–4.808.76–9.757.28–8.142.85–3.64
Range8.8911.5610.928.5
Noneoftheincludedpatientspresentedcomplicationsduringthefollow‐upvisits
(10daysand12‐monthpost‐operation).
Figure5.Linearbonechanges(mm)(mean±95%CI)fordifferenttimepointsin144locations[n=
18patients].p<0.05betweenlocationsandtimepoints.
4.Discussion
Theevaluationoffacialchanges,suchaslossoflipsupport,hasincreasinglybeen
consideredwhenplanningimplant‐supportedrehabilitationofedentulouspatients
[33,34].Aspreviouslyreported,horizontalboneaugmentationinimmediatefull‐arch
reconstructionsisafrequentprocedurethatshouldalsoconsiderthepatient’spreferences,
expectations,andmorbidity[13].Althoughautogenousboneisregardedasthegold
standardgraftmaterialduetoitsosteogenic,osteoinductive,andosteoconductive
properties,itisalsoassociatedwithincreasedmorbidity,alimitedamountofvolume,and
variableresorptionrates[5].Thus,fromapatient‐centeredperspective,cliniciansshould
avoidasecondinvasiveharvestingsurgerytocollectautogenousbone.Toovercomethese
limitations,researchontissueengineeringandhard‐tissueregenerationhasescalatedin
thelasttwodecades[35].Oneofthestrategiesfocusedongrowthfactors,aimingto
modulatecellulareventsinvolvedintissuehealingandrepair[35].Platelet‐richfibrinisa
secondgenerationofAPCsusedinthemanagementofseveremedicalconditions[23].In
dentistry,PRFwasrecognizedasreducingpost‐operativepain,post‐surgicalbleedingin
J.Clin.Med.2022,11,8949of14
patientstakingantiplateletdrugs,andpromotingsofttissueepithelization[28,29].Few
studieshavebeenidentifiedregardingitsuseinhorizontalorverticalboneregeneration
[29,36–38].Totheauthors’bestknowledge,thisisthelargestprospectiveclinicalstudy
conductinganimmediate‐loadingprotocolinthemaxillasimultaneouslywithaGBR
procedureusingamixtureofparticulatexenograftandPRFmembranesembeddedin
liquidfibrinogentoformacompositegraft.
Theresultsofthisprospectiveclinicalstudybasedonasamplesizeof18patients
suggestthatcombiningPRFmembraneswithparticulatedeproteinizedbovinebone
mineralcanbeeffectiveandsafeintreatinghorizontalbonedefectsintheanteriormaxilla
togetherwithimplantplacement.Themeanhorizontalbonegainof3.24[2.85;3.64]mm
observedagreeswiththemainfindingsofsystematicreviewsofrandomizedclinicaltrials
analyzingaGBRtechniqueforlateralridgeaugmentation[15,16,18,19,31,39].Thehigh
heterogeneitybetweenstudiesincludedintheseSRsmayexplainslightlydifferent
outcomesbetweenthem[15,18,39].Namely,Milinkovicetal.describeda3.31mm
horizontalbonegainwhenusingGBR,whereasElnayefetal.reported2.59±0.23mmfor
thesameapproach[15,18].MostoftheincludedGBRstudiesuseddifferenttypesofbone
grafts—eitherautologous,xenogenous,allogenous,oramixtureofboth,withdifferent
typesofmembranesandindifferentedentulousregions.Moreover,severalotherfactors
mayinfluencethemeanhorizontalbonegainoutcome:regenerationtechnique,incision
design,flapmanagement,recipientsitepreparation,graftstability,tension‐freeprimary
closing,anddefectmorphology[5].Ridgeaugmentationproceduresaretechnique‐
sensitiveandrelyontheoperator’sskillfulnessandproficiency[5].Inthisstudy,the
previouslyreferredaspectswereconsistentlymanagedbyasingleexperiencedsurgeon
(J.M.M.C.),exceptdefectmorphology,intrinsictothepatient.
Regardlessofthetechniqueorbiomaterialsused,differentlevelsofgraftresorption
areexpectedtooccur[5,29].Untilnow,fewstudieshaveprovidedinformationaboutbone
graftstabilityatlong‐termfollow‐ups(12months).However,itisrelevantforlong‐term
implantsuccessandfacialaestheticcorrections[18].Thisstudyevaluatedgraftstability
bycomparinghorizontalwidthatthe12‐monthfollow‐upwithpost‐surgicalwidth,and
foundastatisticallydifferentvalue(Friedman’stest,p<0.05)withadrepeatedmeasuresof−1.12
[−1.38;−0.86].mm.Arecentproof‐of‐conceptstudyproposingthecombinationofPRFand
DBBMinhorizontalboneaugmentationreportedanaveragebonegraftstabilityof84.4%
inashorterfollow‐upperiodof5to8months[38].Elanayefetal.alsofoundaslight
horizontalresorptionof1.130.25mmatthe6‐monthfollow‐upforGBRprocedures.
Estimatingthisvalueisextremelyusefulforpredictingthesurgicalapproachand
properlyovercorrectingthebonedefect[40].Intheauthor’sopinion,thisslowresorption
rateisprobablyattributedtothepresenceofxenograft.Thebiocompatibilityand
osteoconductivityofDBBMarewelldocumentedinpre‐clinicalandclinicalstudies.
However,areducedosteoclasticactivitytowardthisbonesubstituteishypothesized[40].
Inaclinicaltrial,ahistomorphometricanalysisshowedthatDBBMparticlesremained
unchangedandintegratedwithinthebonefor11years[41].
GBRinmaxillaboneaugmentationproceduresisusuallyassociatedwithanimplant
survivalrate(ISR)rangingfrom96.1%to100%[12].HigherISRvaluesareobtainedwhen
GBRisperformedsimultaneously,andimplantsareplacedinnativebone[17,39].Itwas
thecaseinthepresentstudy,wherea98.61%ISRwasobtained.Horizontalridge
augmentationwithxenogenousbonegraftisassociatedwithacomplicationrateof7.85%
[19].Membraneexposureisthemostfrequentcomplicationinthistypeofintervention
[19,40].Inthisstudy,nocomplicationswereregisteredduringthefollow‐upvisits.
However,noindicationsorconclusionscanbewithdrawnbasedonthisfindingina
single‐armclinicalstudy.Accordingtoasystematicreview,PRFmembranesare
associatedwithimprovedwoundhealing,softtissueregeneration,andepithelization[42].
Thus,wemightspeculatethatthisadvantagefavoredsofttissuehealingafterahorizontal
boneaugmentationprocedureandsubsequentlyavoidedmembraneandgraftexposure.
ThestandardizationoftheprotocoltoobtainPRFmembranesandliquidfibrinogenwas
J.Clin.Med.2022,11,89410of14
accomplishedaccordingtoapublishedstudyandisanadvantageofthisresearchwork
[26].
Thepresentstudymayentailsomelimitations.Theprimaryoutcomewasassessed
throughlinearmeasurementsofCBCTscans.Severalstudiesappliedasimilar
methodologybymeasuringthehorizontalbonegaininspecificpointsofthealveolar
ridge[31,36,43–45].Althoughregardedasareproduciblemethodtoevaluatebonegain
obtainedafterGBR,dentalimplantsmaycauseartifactsinCBCTimages,reducingimage
qualityandanatomicaccuracy[46].Althoughanyblurredscanwassubjectedtoartifact
correctionbythePlanmecaARA™metalartifactremovalalgorithm,aidingoperator’s
measurements,thismethodologyisnotexemptfromlimitations.
Sincehorizontalboneregenerationrepresentsanaddedbonevolume,thelinear
natureoftheacquiredmeasurementsisaweakpointinthisstudy.Althoughthe
measurementlandmarksarerepresentativeofthegraftingarea,avolumetricdescription
variationwouldbepreferable[38].Basedonthisperspectiveandconsideringthe
developmentofhigh‐speedandhigh‐accuracy3Dintraoralscanners,theiruseinfuture
studiesmayrepresentalessinvasiveoptiontoevaluateboneandsofttissuevolumegain.
IntheGBRtechniqueperformed,PRFmembranesweresolelyusedasabarrierto
coverthecompositePRF/particulateDBBMplacedintheanteriormaxilla’sbonedefect.
Contrarytoasimilarstudyaimingatmaxillahorizontalboneaugmentation,no
resorbablecollagenmembraneorfixationpinswereusedformembranestabilization
underPRFmembranes[38].Whenusingparticulatebonesubstitutesinlargedefectslike
thoseregeneratedinthepresentstudy,membranestabilizationforgraftimmobilization
representsachallengeandkeyfactorforGBRsuccess[17,40].Thisobjectivewasmainly
achievedinthisstudybyaddingliquidfibrinogenbindingbonegraftparticlesinthe
compositePRF/particulateDBBMgraft.Inaddition,thePRFmembranecross‐linking
structureprovidedanelasticmechanicalbehaviorsuitableformembranehandlingand
graftcovering[27].Non‐resorbablemembranesfixatedwithpinsystemsshowless
tendencytocollapseandmaintainthehorizontalcontouroftheaugmentedridge[17].
However,thistypeofapproachpresentsmorecomplications,especiallymembrane
exposure,andrequiresadditionalsurgerytoremovethemembraneandthepinswhen
patientssubjectedtoimmediatefull‐archrehabilitationusuallydonotexpectadditional
surgeryprocedures.Immediate‐loadingsimultaneouslytoboneregenerationhasbeen
poorlydescribedintheliterature[47].Althoughimmediateloadinginmaxillafull‐arch
rehabilitationcanbeapredictableprotocolwhenkeyfactorsareachieved,suchas
adequateprimaryimplantstability,afavorabledrillingtechnique,implantdesign,length,
andimplantmicrostructure[48,49].Inaddition,theimportanceofosteotomytechniques
shouldberecognizedwhenaminimuminsertiontorqueof45N.cmisobtainedinamore
medullarybone[50].Aclearinfluenceofabonecompactorpreparationtoimplant
primarystabilitywassuggestedbyAttanasioetal.inthistypeofbone[50].Inthisstudy,
theoperator(J.M.M.C.)followedbrandinstructionsandaccomplishedanunder‐
preparationscheme,promotingamorefrictionalimplantinsertion.Otheraspects,suchas
cross‐archstabilization,prostheticmaterial,andprostheticrehabilitationdesignaidedto
unloadtheregeneratedarea—acrucialaspectoftheboneregenerationprocess.
Becausethisstudyisasingle‐armprospectiveclinicalstudywithoutanycomparison
group,theconclusionsregardingtheuseofPRFinhorizontalboneaugmentationare
limited.AnRCTstudydesignwouldhavethepotentialtobetterclarifythediscussed
biologicalbenefits.AmajoraspectofthebiologicalplausibilityproposedforPRFinbone
regenerationshouldalsobequestioned.Fibrinmatrixdegradationandgrowthfactor
releaseoccurinthefirst10to14days,whereasbonetissueformationoccursin3to4
months[27].Itiseasilyperceivedthatthisnaturalscaffoldlacksaspatial‐temporal
deliveryofgrowthfactorsconcomitanttoboneformationevents.Sinceitderivesfrom
blood,itsspecificity,andminimumconcentrationofgrowthfactorstoaidosteogenesis’s
initialphasesarestillunknown.Therefore,futureresearchshouldaimtoclarifythis
questionandoptimizescaffoldspreparedinordertoassistalleventsofbonetissue
J.Clin.Med.2022,11,89411of14
formation,providingacombinedreleaseofgrowthfactorsandextracellularmatrix
components.
5.Conclusions
Withinthelimitationsofthisclinicalstudy,theuseofcompositePRF/particulate
xenograftinGBRforhorizontalboneaugmentationwithsimultaneousimplantplacement
seemssafeandprovidesahorizontalbonegainandgraftstabilitywithinpreviously
describedvaluesforGBRprocedures.Thisresultmightbeparticularlyrelevantsinceno
resorbablecollagenmembraneswereusedtocoveranimmobilizedbonegraftobtained
byaddingliquidfibrinogen.Notypeofcomplicationhasbeenregistered.Furtherstudies
areneededtovalidateorexcludethepotentialbiologicalbenefitsofPRFinGBR
proceduresformaxillahorizontalboneaugmentation.
AuthorContributions:Conceptualization,J.M.M.C.andD.N.d.S.M.;methodology,D.N.d.S.M.;
investigation,J.M.M.C.,G.B.C.,H.C.O.F.,A.C.P.andF.A.V.;supervision,D.N.d.S.M.;surgery
performance,J.M.M.C.;visualization,G.B.C.andH.C.O.F.;writing—originaldraftpreparation,
F.A.V.;writing—reviewandediting,D.N.d.S.M.,F.A.V.andJ.M.M.C.Allauthorshavereadand
agreedtothepublishedversionofthemanuscript.
Funding:Thisstudydidnotreceiveexternalfunding.
InstitutionalReviewBoardStatement:Thestudywasconductedaccordingtotheguidelinesofthe
DeclarationofHelsinkiandapprovedbytheInstitutionalReviewBoardandEthicsCommitteein
Lisbon(II‐04‐2019).
InformedConsentStatement:Informedconsentwasobtainedfromeachpatientconsideredfor
dataanalysis.
DataAvailabilityStatement:Datacannotbesharedduetodataprotectionobligations.
ConflictsofInterest:Theauthorsdeclarenoconflictofinterest.
Abbreviations
PRFPlatelet‐richfibrin
CBCTConebeamcomputedtomography
GBRGuidedboneregeneration
APCsAutologousplateletconcentrates(APCs)
PDGFPlateletderivedgrowthfactor
TGF‐
β
1Transforminggrowthfactor
β
1
IGFInsulin‐likegrowthfactor
VEGFVascularendothelialgrowthfactor
DBBMDeproteinizedbovinebonemineral
ASAAmericanSocietyofAnesthesiology(physicalstatusclassificationscoreI‐VI)
MRONJMedicationrelatedtoosteonecrosisofthejaw
SRsSystematicreviews
ISRImplantsurvivalrate
RCTRandomizedclinicaltrial
References
1. Mertens,C.;Freier,K.;Engel,M.;Krisam,J.;Hoffmann,J.;Freudlsperger,C.Reconstructionoftheseverelyatrophicedentulous
maxillaewithcalvarialbonegrafts.Clin.OralImplant.Res.2016,28,749–756,https://doi.org/10.1111/clr.12873.
2. Gallucci,G.O.;Avrampou,M.;Taylor,J.C.;Elpers,J.;Thalji,G.;Cooper,L.MaxillaryImplant‐SupportedFixedProsthesis:A
SurveyofReviewsandKeyVariablesforTreatmentPlanning.Int.J.OralMaxillofac.Implant.2017,31,s192–s197,
https://doi.org/10.11607/jomi.16suppl.g5.3.
3. Tan,W.L.;Wong,T.L.T.;Wong,M.C.M.;Lang,N.P.Asystematicreviewofpost‐extractionalalveolarhardandsofttissue
dimensionalchangesinhumans.Clin.OralImplant.Res.2012,23(Suppl.S5),1–21,https://doi.org/10.1111/j.1600‐
0501.2011.02375.x.
4. VanDerWeijden,F.;DellʹAcqua,F.;Slot,D.E.Alveolarbonedimensionalchangesofpost‐extractionsocketsinhumans:A
systematicreview.J.Clin.Periodontol.2009,36,1048–1058,https://doi.org/10.1111/j.1600‐051x.2009.01482.x.
J.Clin.Med.2022,11,89412of14
5. Chiapasco,M.;Casentini,P.Horizontalbone‐augmentationproceduresinimplantdentistry:Prostheticallyguided
regeneration.Periodontology20002018,77,213–240,https://doi.org/10.1111/prd.12219.
6. Sutton,D.;Lewis,B.;Patel,M.;Cawood,J.Changesinfacialformrelativetoprogressiveatrophyoftheedentulousjaws.Int.J.
OralMaxillofac.Surg.2004,33,676–682,https://doi.org/10.1016/s0901‐5027(03)00132‐2.
7. Bidra,A.S.Three‐DimensionalEstheticAnalysisinTreatmentPlanningforImplant‐SupportedFixedProsthesisinthe
EdentulousMaxilla:ReviewoftheEstheticsLiterature.J.Esthet.Restor.Dent.2011,23,219–236,https://doi.org/10.1111/j.1708‐
8240.2011.00428.x.
8. Pollini,A.;Goldberg,J.;Mitrani,R.;Morton,D.TheLip‐Tooth‐RidgeClassification:AGuidepostforEdentulousMaxillary
Arches.Diagnosis,RiskAssessment,andImplantTreatmentIndications.Int.J.PeriodonticsRestor.Dent.2017,37,835–841,
https://doi.org/10.11607/prd.3209.
9. Kuchler,U.;vonArx,T.Horizontalridgeaugmentationinconjunctionwithorpriortoimplantplacementintheanterior
maxilla:Asystematicreview.Int.J.OralMaxillofac.Implant.2014,29,14–24.
10. Cordaro,M.;Donno,S.;Ausenda,F.;Cordaro,L.InfluenceofBoneAnatomyonImplantPlacementProceduresinEdentulous
ArchesofElderlyIndividuals:ACross‐SectionalStudyonComputedTomographyImages.Int.J.OralMaxillofac.Implant.2020,
35,995–1004,https://doi.org/10.11607/jomi.8297.
11. Pommer,B.;Mailath‐Pokorny,G.;Haas,R.;Busenlechner,D.;Fürhauser,R.;Watzek,G.Patientsʹ preferencestowards
minimallyinvasivetreatmentalternativesforimplantrehabilitationofedentulousjaws.Eur.J.OralImplant.2014,7(Suppl.S2),
S91–S109.
12. Aghaloo,T.L.;Misch,C.;Lin,G.‐H.;Iacono,V.J.;Wang,H.‐L.BoneAugmentationoftheEdentulousMaxillaforImplant
Placement:ASystematicReview.Int.J.OralMaxillofac.Implant.2017,31,s19–s30,https://doi.org/10.11607/jomi.16suppl.g1.
13. Caramês,J.M.M.;Marques,D.N.D.S.;Caramês,G.B.;Francisco,H.C.O.;Vieira,F.A.ImplantSurvivalinImmediatelyLoaded
Full‐ArchRehabilitationsFollowinganAnatomicalClassificationSystem—ARetrospectiveStudyin1200EdentulousJaws.J.
Clin.Med.2021,10,5167,https://doi.org/10.3390/jcm10215167.
14. Elnayef,B.;Monje,A.;Lin,G.‐H.;Gargallo‐Albiol,J.;Chan,H.‐L.;Wang,H.‐L.;Hernández‐Alfaro,F.AlveolarRidgeSpliton
HorizontalBoneAugmentation:ASystematicReview.Int.J.OralMaxillofac.Implant.2015,30,596–606,
https://doi.org/10.11607/jomi.4051.
15. Milinkovic,I.;Cordaro,L.Aretherespecificindicationsforthedifferentalveolarboneaugmentationproceduresforimplant
placement?Asystematicreview.Int.J.OralMaxillofac.Surg.2014,43,606–625,https://doi.org/10.1016/j.ijom.2013.12.004.
16. Esposito,M.;Grusovin,M.G.;Felice,P.;Karatzopoulos,G.;Worthington,H.;Coulthard,P.TheEfficacyofHorizontaland
VerticalBoneAugmentationProceduresforDentalImplants:ACochraneSystematicReview.Eur.J.OralImplant.2009,2,167–
184https://doi.org/10.1007/978‐3‐642‐05025‐1_13.
17. Wessing,B.;Lettner,S.;Zechner,W.GuidedBoneRegenerationwithCollagenMembranesandParticulateGraftMaterials:A
SystematicReviewandMeta‐Analysis.Int.J.OralMaxillofac.Implant.2018,33,87–100,https://doi.org/10.11607/jomi.5461.
18. Elnayef,B.;Porta,C.;Suárez‐LópezdelAmo,F.;Mordini,L.;Gargallo‐Albiol,J.;Hernández‐Alfaro,F.TheFateofLateralRidge
Augmentation:ASystematicReviewandMeta‐Analysis.Int.J.OralMaxillofac.Implant.2018,33,622–635,
https://doi.org/10.11607/jomi.6290.
19. Carvalho,P.H.D.A.;Trento,G.D.S.;Moura,L.B.;Cunha,G.;Gabrielli,M.A.C.;Pereira‐Filho,V.A.Horizontalridge
augmentationusingxenogenousbonegraft—Systematicreview.OralMaxillofac.Surg.2019,23,271–279,
https://doi.org/10.1007/s10006‐019‐00777‐y.
20. Jung,R.E.;Fenner,N.;Hämmerle,C.H.;Zitzmann,N.U.Long‐termoutcomeofimplantsplacedwithguidedboneregeneration
(GBR)usingresorbableandnon‐resorbablemembranesafter12–14years.Clin.OralImplant.Res.2013,24,1065–1073.
21. Dahlin,C.;Linde,A.;Gottlow,J.;Nyman,S.HealingofBoneDefectsbyGuidedTissueRegeneration.Plast.Reconstr.Surg.1988,
81,672–676,https://doi.org/10.1097/00006534‐198805000‐00004.
22. Miron,R.J.;Zucchelli,G.;Pikos,M.A.;Salama,M.;Lee,S.;Guillemette,V.;Fujioka‐Kobayashi,M.;Bishara,M.;Zhang,Y.;Wang,
H.‐L.;etal.Useofplatelet‐richfibrininregenerativedentistry:Asystematicreview.Clin.OralInvestig.2017,21,1913–1927,
https://doi.org/10.1007/s00784‐017‐2133‐z.
23. Fortunato,L.;Barone,S.;Bennardo,F.;Giudice,A.ManagementofFacialPyodermaGangrenosumUsingPlatelet‐RichFibrin:
ATechnicalReport.J.OralMaxillofac.Surg.2018,76,1460–1463,https://doi.org/10.1016/j.joms.2018.01.012.
24. Dohan,D.M.;Choukroun,J.;Diss,A.;Dohan,S.L.;Dohan,A.J.;Mouhyi,J.;Gogly,B.Platelet‐richfibrin(PRF):Asecond‐
generationplateletconcentrate.PartI:Technologicalconceptsandevolution.OralSurg.OralMed.OralPathol.OralRadiol.Endod.
2006,101,e37–e44.
25. DohanEhrenfest,D.M.;Pinto,N.R.;Pereda,A.;Jiménez,P.;DelCorso,M.;Kang,B.‐S.;Nally,M.;Lanata,N.;Wang,H.‐L.;
Quirynen,M.Theimpactofthecentrifugecharacteristicsandcentrifugationprotocolsonthecells,growthfactors,andfibrin
architectureofaleukocyte‐ andplatelet‐richfibrin(L‐PRF)clotandmembrane.Platelets2018,29,171–184,
https://doi.org/10.1080/09537104.2017.1293812.
26. Temmerman,A.;Vandessel,J.;Castro,A.;Jacobs,R.;Teughels,W.;Pinto,N.;Quirynen,M.Theuseofleucocyteandplatelet‐
richfibrininsocketmanagementandridgepreservation:Asplit‐mouth,randomized,controlledclinicaltrial.J.Clin.Periodontol.
2016,43,990–999,https://doi.org/10.1111/jcpe.12612.
J.Clin.Med.2022,11,89413of14
27. Fujioka‐Kobayashi,M.;Katagiri,H.;Kono,M.;Schaller,B.;Zhang,Y.;Sculean,A.;Miron,R.J.Improvedgrowthfactordelivery
andcellularactivityusingconcentratedplatelet‐richfibrin(C‐PRF)whencomparedwithtraditionalinjectable(i‐PRF)protocols.
Clin.OralInvestig.2020,24,4373–4383,https://doi.org/10.1007/s00784‐020‐03303‐7.
28. Brancaccio,Y.;Antonelli,A.;Barone,S.;Bennardo,F.;Fortunato,L.;Giudice,A.Evaluationoflocalhemostaticefficacyafter
dentalextractionsinpatientstakingantiplateletdrugs:Arandomizedclinicaltrial.Clin.OralInvestig.2021,25,1159–1167.
29. Sanz,M.;Dahlin,C.;Apatzidou,D.;Artzi,Z.;Bozic,D.;Calciolari,E.;DeBruyn,H.;Dommisch,H.;Donos,N.;Eickholz,P.;et
al.Biomaterialsandregenerativetechnologiesusedinboneregenerationinthecraniomaxillofacialregion:Consensusreportof
group2ofthe15thEuropeanWorkshoponPeriodontologyonBoneRegeneration.J.Clin.Periodontol.2019,46(Suppl.S21),82–
91,https://doi.org/10.1111/jcpe.13123.
30. Dragonas,P.;Katsaros,T.;Ortiz,G.A.;Chambrone,L.;Schiavo,J.;Palaiologou,A.Effectsofleukocyte–platelet‐richfibrin(L‐
PRF)indifferentintraoralbonegraftingprocedures:Asystematicreview.Int.J.OralMaxillofac.Surg.2019,48,250–262,
https://doi.org/10.1016/j.ijom.2018.06.003.
31. Mordenfeld,A.;Johansson,C.B.;Albrektsson,T.;Hallman,M.Arandomizedandcontrolledclinicaltrialoftwodifferent
compositionsofdeproteinizedbovineboneandautogenousboneusedforlateralridgeaugmentation.Clin.OralImplant.Res.
2014,25,310–320,https://doi.org/10.1111/clr.12143.
32. Caramês,J.;DaMata,A.D.S.P.;Marques,D.N.D.S.;Francisco,H.Ceramic‐VeneeredZirconiaFrameworksinFull‐ArchImplant
Rehabilitations:A6‐Monthto5‐YearRetrospectiveCohortStudy.Int.J.OralMaxillofac.Implant.2016,31,1407–1414,
https://doi.org/10.11607/jomi.4675.
33. Calvani,L.;Michalakis,K.;Hirayama,H.Theinfluenceoffull‐archimplant‐retainedfixeddentalprosthesesonupperlip
supportandlowerfacialesthetics:Preliminaryclinicalobservations.Eur.J.Esthet.Dent.2007,2,420–428.
34. Uhlendorf,Y.;deMattiasSartori,I.A.;MoreiraMelo,A.C.;Uhlendorf,J.ChangesinLipProfileofEdentulousPatientsAfter
PlacementofMaxillaryImplant‐SupportedFixedProsthesis:IsaWaxTry‐inaReliableDiagnosticTool?Int.J.OralMaxillofac.
Implant.2017,32,593–597.
35. Pilipchuk,S.P.;Plonka,A.B.;Monje,A.;Taut,A.D.;Lanis,A.;Kang,B.;Giannobile,W.V.Tissueengineeringforbone
regenerationandosseointegrationintheoralcavity.Dent.Mater.2015,31,317–338,https://doi.org/10.1016/j.dental.2015.01.006.
36. Valladão,C.A.A.,Jr.;Monteiro,M.F.;Joly,J.C.Guidedboneregenerationinstagedverticalandhorizontalboneaugmentation
usingplatelet‐richfibrinassociatedwithbonegrafts:Aretrospectiveclinicalstudy.Int.J.ImplantDent.2020,6,1–10,
https://doi.org/10.1186/s40729‐020‐00266‐y.
37. Hartlev,J.;Nørholt,S.E.;Spin‐Neto,R.;Kraft,D.;Schou,S.;Isidor,F.Histologyofaugmentedautogenousbonecoveredbya
platelet‐richfibrinmembraneordeproteinizedbovinebonemineralandacollagenmembrane:Apilotrandomizedcontrolled
trial.Clin.OralImplant.Res.2020,31,694–704,https://doi.org/10.1111/clr.13605.
38. Cortellini,S.;Castro,A.B.;Temmerman,A.;VanDessel,J.;Pinto,N.;Jacobs,R.;Quirynen,M.Leucocyte‐andplatelet‐richfibrin
blockforboneaugmentationprocedure:Aproof‐of‐conceptstudy.J.Clin.Periodontol.2018,45,624–634,
https://doi.org/10.1111/jcpe.12877.
39. Sanz‐Sánchez,I.;Ortiz‐Vigón,A.;Sanz‐Martín,I.;Figuero,E.;Sanz,M.EffectivenessofLateralBoneAugmentationonthe
AlveolarCrestDimension:ASystematicReviewandMeta‐analysis.J.Dent.Res.2015,94(Suppl.S9),128s–142s.
40. Benic,G.I.;Hämmerle,C.H.F.Horizontalboneaugmentationbymeansofguidedboneregeneration.Periodontology20002014,
66,13–40,https://doi.org/10.1111/prd.12039.
41. Mordenfeld,A.;Hallman,M.;Johansson,C.B.;Albrektsson,T.Histologicalandhistomorphometricalanalysesofbiopsies
harvested11yearsaftermaxillarysinusflooraugmentationwithdeproteinizedbovineandautogenousbone.Clin.OralImplant.
Res.2010,21,961–970,https://doi.org/10.1111/j.1600‐0501.2010.01939.x.
42. Miron,R.J.;Fujioka‐Kobayashi,M.;Bishara,M.;Zhang,Y.;Hernandez,M.;Choukroun,J.Platelet‐RichFibrinandSoftTissue
WoundHealing:ASystematicReview.TissueEng.PartB:Rev.2017,23,83–99,https://doi.org/10.1089/ten.teb.2016.0233.
43. Lumetti,S.;Galli,C.;Manfredi,E.;Consolo,U.;Marchetti,C.;Ghiacci,G.;Toffoli,A.;Bonanini,M.;Salgarelli,A.;Macaluso,
G.M.CorrelationbetweenDensityandResorptionofFresh‐FrozenandAutogenousBoneGrafts.BioMedRes.Int.2014,2014,
508328,https://doi.org/10.1155/2014/508328.
44. Castagna,L.;Polido,W.;Soares,L.;Tinoco,E.Tomographicevaluationofiliaccrestbonegraftingandtheuseofimmediate
temporaryimplantstotheatrophicmaxilla.Int.J.OralMaxillofac.Surg.2013,42,1067–1072,
https://doi.org/10.1016/j.ijom.2013.04.020.
45. Amorfini,L.;Migliorati,M.;Signori,A.;Silvestrini‐Biavati,A.;Benedicenti,S.BlockAllograftTechniqueversusStandard
GuidedBoneRegeneration:ARandomizedClinicalTrial.Clin.ImplantDent.Relat.Res.2013,16,655–667,
https://doi.org/10.1111/cid.12040.
46. Sheridan,R.A.;Chiang,Y.‐C.;Decker,A.M.;Sutthiboonyapan,P.;Chan,H.‐L.;Wang,H.‐L.TheEffectofImplant‐Induced
ArtifactsonInterpretingAdjacentBoneStructuresonCone‐BeamComputedTomographyScans.ImplantDent.2018,27,10–14,
https://doi.org/10.1097/id.0000000000000684.
47. Shibly,O.;Patel,N.;Albandar,J.M.;Kutkut,A.BoneRegenerationaroundImplantsinPeriodontallyCompromisedPatients:A
RandomizedClinicalTrialoftheEffectofImmediateImplantwithImmediateLoading.J.Periodontol.2010,81,1743–1751,
https://doi.org/10.1902/jop.2010.100162.
48. Jiang,X.;Zhou,W.;Wu,Y.;Wang,F.ClinicalOutcomesofImmediateImplantLoadingwithFixedProsthesesinEdentulous
Maxillae:ASystematicReview.Int.J.OralMaxillofac.Implant.2021,36,503–519,https://doi.org/10.11607/jomi.8509.
J.Clin.Med.2022,11,89414of14
49. Gapski,R.;Wang,H.‐L.;Mascarenhas,P.;Lang,N.P.Criticalreviewofimmediateimplantloading.Clin.OralImplant.Res.2003,
14,515–527,https://doi.org/10.1034/j.1600‐0501.2003.00950.x.
50. Attanasio,F.;Antonelli,A.;Brancaccio,Y.;Averta,F.;Figliuzzi,M.M.;Fortunato,L.;Giudice,M.PrimaryStabilityofThree
DifferentOsteotomyTechniquesinMedullaryBone:AninVitroStudy.Dent.J.2020,8,21,https://doi.org/10.3390/dj8010021.